<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112540">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01779466</url>
  </required_header>
  <id_info>
    <org_study_id>000088</org_study_id>
    <secondary_id>2012-004388-34</secondary_id>
    <nct_id>NCT01779466</nct_id>
  </id_info>
  <brief_title>Daytime Impact Sleep Study</brief_title>
  <acronym>DAISS</acronym>
  <official_title>A Double-blind, Randomised, Parallel-group Trial Investigating Sleep Behaviour and Daytime Performance in Nocturia Patients Treated With Desmopressin Orally Disintegrating Tablets as Compared to Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will investigate the relationship of sleep, daytime performance and nocturia in
      patients treated with Desmopressin or placebo. Male and Female patients will be administered
      Desmopressin or Placebo every day for 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to lack of eligible patients
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean number of nocturnal voids</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured by voiding diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wake after sleep onset</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>i.e. time in minutes of epochs scored as wake from sleep onset latency until lights on. Measured by Polysomnography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daytime sleepiness score as measured by Karolinska Sleepiness Scale and Epworth Sleepiness Scale</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Daytime performance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean time to first void</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured by voiding diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep efficiency</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleep efficiency equals total sleep time divided by total recording time multiplied by 100. Measured by Polysomnography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep stage N1, N2, N3, (sleep stages in NREM (non-rapid eye movement) and REM (rapid eye movement) as a percentage of total sleep time</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by Polysomnography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of awakenings due to nocturia</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by Polysomnography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Latency to slow-wave sleep</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by Polysomnography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wake after sleep onset (WASO) i.e total minutes of wakefulness recorded after sleep onset</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by Actigraphy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of sleep</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by Actigraphy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of awakenings due to nocturia</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by Actigraphy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life score measured by EQ-5D-5L</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Daytime performance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - incidence of adverse events</measure>
    <time_frame>1 month and 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - clinically significant changes in lab values</measure>
    <time_frame>1 week and 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - clinically significant changes in vital signs</measure>
    <time_frame>1 week, 1 month and 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - clinically significant changes in physical examination</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>Experimental A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmopressin</intervention_name>
    <arm_group_label>Experimental A</arm_group_label>
    <arm_group_label>Experimental B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (not active)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 2 night time voids per night

          -  Habitual sleep of  6-9.5 hours per night

          -  Experiencing symptoms of Nocturia greater than 6 months

        Exclusion Criteria:

          -  Greater than 10 night time voids

          -  History of sleep apnoea and PLMS (Periodic Limb Movements of Sleep)

          -  Other sleep disorders

          -  Signs or symptoms of: Bladder outlet obstruction, severe lower urinary tract symptoms
             (LUTS), interstitial cystitis, moderate to severe overactive bladder (OAB), moderate
             to severe as judged by the investigator stress urinary incontinence

          -  Urological malignancies

          -  Neurogenic detrusor over activity (e.g. Parkinson, spinal cord damage, etc.)

          -  Central or nephrogenic diabetes insipidus

          -  Habitual or psychogenic polydipsia (fluid intake resulting in a urine production
             exceeding 40ml/Kg/24hrs)

          -  Syndrome of inappropriate antidiuretic hormone (SIADH)

          -  Cardiac failure evidence based on physical examination, cardiac medical history and
             electrocardiogram (ECG) output

          -  Uncontrolled hypertension

          -  Uncontrolled diabetes mellitus

          -  Hyponatraemia with sodium &lt;135 mmol/L

          -  Renal insufficiency

          -  Known or suspected clinically significant hepatic and/or biliary diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surrey Clinical Research Centre</name>
      <address>
        <city>Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>January 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
